1151 ET - Tilray's recent run of weak Canadian adult-use cannabis sales should start to turn around now that the company has completed capital investments aimed at sprucing up its participation in the vape and infused pre-roll categories, TD Cowen analysts say in a research note. The company had been choosing not to participate in the two categories, which carry higher taxes and lower margins, as they were seeing significant price deflation across the industry, the analysts say. But Tilray recently invested in a facility that allows it to use more cannabis byproducts as inputs for vapes and infused pre-rolls, allowing for better economies of scale, they say. The facility is now operational, so adult-use trends should improve sequentially in 3Q, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 11:51 ET (16:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.